Fig. 1.

Pretreatment effects on CYP2D and CYP2D6 in brain and liver of TG and WT. Four-hour ICV propranolol pretreatment irreversibly inhibits human CYP2D6 in TG brain and competitively inhibits mouse CYP2D in TG and WT brain. Twenty-four-hour ICV propranolol pretreatment irreversibly inhibits human CYP2D6 in TG brain but no longer inhibits mouse CYP2D in TG or WT brain. Following 4-and 24-h ICV propranolol pretreatments, there is no inhibition of human CYP2D6 in TG liver, or of mouse CYP2D in TG or WT liver, indicating that propranolol given ICV does not reach the liver in sufficient amounts to alter hepatic metabolism. For more details, see text and Tolledo et al. [34]